| Document |
Document Title |
|
WO/2021/050681A1 |
Disclosed herein, inter alia, are methods for modifying a nucleotide, for example including reacting a nucleotide having a 3'-O-oxime moiety with a reagent having the structure R2-ONH2 to produce a nucleotide having a 3'-O-NH2 moiety, wh...
|
|
WO/2021/050961A1 |
Provided herein are compounds, compositions and methods of using thereof for treatment and/or prevention infections of viruses such as HIV and HBV by administering a certain esters and other derivatives of 4'-ethynyl-2-fluoro-2'-deoxyade...
|
|
WO/2021/050956A1 |
Diesters of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and aqueous parenteral suspensions thereof provide extended in vivo viral suppression of human immunodeficiency virus (HIV).
|
|
WO/2021/046355A1 |
The present disclosure describes a method for treating mitochondrial DNA depletion syndrome by administration of a therapeutic amount of a composition comprising a dinucleotide compound or a mixture thereof. Further described herein are ...
|
|
WO/2021/046357A1 |
The present invention provides a composition comprising adenosine or adenosine triphosphate (ATP) acting as an absorption enhancer when combined with a nutritional material(s) such as nutrients, protein, peptides, vitamins, phytochemical...
|
|
WO/2021/039935A1 |
Provided are: a nucleic acid compound manufacturing method that uses a nucleic acid compound that is preserved by a structure in which either one of the third position or fifth position of a ribose structure is represented by formula (1)...
|
|
WO/2021/041756A1 |
The present invention relates to methods for synthesizing compounds useful as potent and stable RNA interference agents, derivatives thereof, and intermediates thereto.
|
|
WO/2021/038509A1 |
The invention relates to compounds of Formulae (I)-(II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
|
|
WO/2021/032075A1 |
Provided herein is a prodrug platform useful to deliver pharmaceutically active amines, amides and phenols and their use in the diagnosis, prevention and/or treatment of various diseases. Compared with the parent drug (e.g., Gemcitabine)...
|
|
WO/2021/031109A1 |
Provided is a method for sequencing polynucleotides on the basis of optical signal dynamics of a luminescent label and a secondary luminescent signal, wherein different luminescent forms and luminescent timings are used to distinguish th...
|
|
WO/2021/034962A1 |
Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein. Also provided are compositions comprising polymorphic forms of deoxycytidine and at least one residual solvent, as well as methods of treating mit...
|
|
WO/2021/028336A1 |
The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, R1a, R1b, and R2 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to ph...
|
|
WO/2021/030551A1 |
The invention relates to compounds and compositions for differential modulation of nicotinamide adenine dinucleotide (NAD) in various tissues or cell types. Further, the invention relates to pharmaceutical compositions containing one or ...
|
|
WO/2021/027614A1 |
A modified cytidine compound, that is, an aminooxy group is modified at the 4-position of a cytidine pyrimidine ring to produce derivative cytidine and nucleic acid containing the derivative cytidine, such as RNA. The expression level of...
|
|
WO/2021/030778A1 |
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified intemucleoside linking group.
|
|
WO/2021/028323A1 |
The present invention relates to compounds of Formula (I) Formula (I) wherein Ar1, R1, R2a, R2b, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuti...
|
|
WO/2021/024114A1 |
The invention relates to compounds of Formulae (I) and (II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
|
|
WO/2021/023252A1 |
Acridinium ester-containing compounds are provided herein. Also provided herein are chemiluminescence-based one-color sequencing methods and methods of using the acridinium ester-containing compounds in chemiluminescence-based one-color ...
|
|
WO/2021/020879A1 |
The present disclosure provides the dinucleotide compounds which is useful for treating various cancers. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disc...
|
|
WO/2021/013795A2 |
The present invention relates to a method of making nicotinamide ribofuranosie salts, in particular pharmaceutically acceptable nicotinamide ribofuranoside salts. The invention further relates to the nicotinamide ribofuranoside salts as ...
|
|
WO/2021/011692A1 |
Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.
|
|
WO/2021/004940A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; ...
|
|
WO/2021/007283A1 |
Described herein are methods of treating RNA virus infections with a therapeutic combination of an antiviral nucleobase compound and a de novo nucleotide biosynthesis inhibitor (DNNBi). An aspect of the invention is a method for the trea...
|
|
WO/2021/001528A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflamm...
|
|
WO/2021/000380A1 |
The present disclosure relates to the technical field of nucleic acid medicines, in particular to a modified nucleoside, a nucleotide and a modified nucleic acid polymer, as well as a preparation method therefor and an application thereo...
|
|
WO/2021/001329A1 |
The invention relates to a new process for the preparation of high water affinity type products with controlled humidity via spray drying in a suitable spray drying equipment applying specific spray drying parameters.
|
|
WO/2021/001538A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; Inflammatio...
|
|
WO/2020/260351A1 |
The present invention relates to a process for preparing a compound of formula (I), wherein said process is suitable for large scale synthesis.
|
|
WO/2020/257429A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2020/253872A1 |
2-Benzylidene hydrazinoadenosine compounds having A2A adenosine receptor agonistic activity, represented by a general formula (I) and pharmaceutical compositions containing the same. The compounds and compositions may act as A2A adenosin...
|
|
WO/2020/256084A1 |
A crystal of a compound represented by formula 5. In formula 5, R1 represents a hydroxyl protecting group, and R2 represents a leaving group.
|
|
WO/2020/255978A1 |
[Problem] To provide a novel phosphate ester compound having a pyrrolopyrimidine skeleton or a pharmaceutically acceptable salt thereof which has excellent antitumor effects, and a method for preventing and/or treating a tumor that is us...
|
|
WO/2020/253866A1 |
The present invention relates to a compound represented by formula I or a pharmaceutically acceptable salt, stereoisomeride, pharmaceutically acceptable hydrate or solvate, or pharmaceutically acceptable ester thereof, wherein R is selec...
|
|
WO/2020/253867A1 |
The present application provides a small-molecule compound, represented by general formula (I), having A2A adenosine receptor antagonistic activity and a pharmaceutical composition containing same. The compound and composition can be use...
|
|
WO/2020/253870A1 |
The present disclosure provides 6-hydrazinoadenosine having A2A adenosine receptor agonistic activity represented by general formula (I) and a derivative thereof, and a pharmaceutical composition containing same. The compound and composi...
|
|
WO/2020/257283A1 |
The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have ...
|
|
WO/2020/255979A1 |
[Problem] To provide: a novel carbonate compound of nucleotides which has a pyrrolopyrimidine skeleton and exhibits an excellent antitumor effect, or a pharmaceutically acceptable salt thereof; and a method for preventing and/or treating...
|
|
WO/2020/248068A1 |
The present application provides a synthetic method for production of 3-azido-3-deoxy-D-galactopyranose. Also provided are methods of using the 3-azido-3-deoxy-D-galactopyranose in the manufacture of galactoside galectin antagonists, suc...
|
|
WO/2020/252380A2 |
The present disclosure is concerned with 2,4,7-substituted-7-deaza-2'-deoxy-2'- fluoroarabinosyl nucleoside and nucleotide prodrugs that are capable of inhibiting viral infections and methods of treating viral infections such as, for exa...
|
|
WO/2020/245191A1 |
The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and/or treatment of skeletal muscle disease and/or conditions. In one embodiment of the invention, said c...
|
|
WO/2020/247818A1 |
Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a disease which utilize...
|
|
WO/2020/246616A1 |
[Problem] To provide a novel fluorescent probe. [Solution] The compound represented by general formula (I), or a salt thereof.
|
|
WO/2020/247546A1 |
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
|
|
WO/2020/247782A1 |
Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize ...
|
|
WO/2020/235658A1 |
Provided are a multi-fluorous blockmer capable of reducing the purification burden using a readily available fluorous tag, and an oligonucleotide synthesis method using the same. A multi-fluorous blockmer represented by the formula is sy...
|
|
WO/2020/227132A1 |
Provided herein are prodrugs of 5-fluorodeoxyuridine monophosphate compounds, compositions thereof, methods of their preparation, and their use in treating cancers. In another aspect, provided herein is a pharmaceutical composition compr...
|
|
WO/2020/227421A1 |
Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutical...
|
|
WO/2020/223530A1 |
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.
|
|
WO/2020/221209A1 |
A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are...
|
|
WO/2020/219417A1 |
Compounds, compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition associated with E-selectin, galectin-3, and/or CXCR4 chemokine receptor activity are disclosed herein. For example, mult...
|
